Spravato (Esketamine)

Esketamine is a medicine used to treat depression that hasn't gotten better with other treatments, and depression with thoughts of suicide. It's a nasal spray you use at a clinic while a healthcare provider watches, and you stay for at least two hours afterward to be checked. It works on a brain chemical called glutamate to help mood improve quickly.

Brand names:Spravato
Medication

What people taking Spravato (Esketamine) report

Every report comes from a Lived member, sent anonymously.

Have you tried Spravato (Esketamine) for Treatment-Resistant Depression?

NameHow it went

About Spravato (Esketamine)

What It's For

Esketamine, sold under the brand name Spravato, is a prescription nasal spray for adults whose depression has been hard to treat. It is approved for treatment-resistant depression, meaning major depression that has not improved enough despite trying other antidepressants, and it can be used on its own or alongside an oral antidepressant. It is also approved, together with an oral antidepressant, to treat depressive symptoms in adults with major depressive disorder who are having acute suicidal thoughts or behavior. Esketamine is a form of ketamine, a medicine long used for anesthesia. Spravato is not approved as an anesthetic, and it is a different product from the intravenous ketamine some clinics offer off-label. For people in a suicidal crisis, it has not been shown to prevent suicide or to reduce suicidal thinking itself, and it does not replace hospital care when that is needed. It is not approved for anyone under 18.

How It Works

Most antidepressants, such as SSRIs (selective serotonin reuptake inhibitors), act on serotonin or related chemical messengers. Esketamine works on a different system. It blocks the NMDA (N-methyl-D-aspartate) receptor, a docking site for glutamate, the brain's main excitatory messenger, which is involved in how nerve cells communicate and adapt. Exactly how this produces an antidepressant effect is not known. What sets it apart in practice is speed. In studies, some improvement over placebo appeared within hours to a couple of days, rather than the several weeks standard antidepressants usually need. Because it acts on the same receptor as ketamine, it also causes ketamine's short-lived effects on alertness and perception, which is why every dose is given under supervision.

Dosage & Administration

Spravato is only given in a certified clinic or medical office enrolled in a federal safety program called a REMS (Risk Evaluation and Mitigation Strategy). You use the spray yourself while a healthcare provider watches. Each device delivers 28 mg, so a 56 mg or 84 mg dose means using two or three devices, with a five-minute rest between them. Blood pressure is checked before the dose and again about 40 minutes later, when the rise usually peaks, and you stay under observation for at least two hours, with your breathing and oxygen level monitored, until staff judge you ready to leave. For treatment-resistant depression, sessions are usually twice a week for the first four weeks, then weekly for the next four, then weekly or every other week, using the least frequent schedule that keeps symptoms under control. For depression with acute suicidal thoughts, the usual course is twice a week for four weeks; longer use for this purpose has not been well studied. To reduce nausea, avoid eating for two hours before a session and avoid drinking for 30 minutes. If you need a nasal steroid or decongestant spray that day, use it at least an hour beforehand. You cannot drive yourself home: arrange a ride, and do not drive or operate machinery until the next day after a restful night's sleep.

Side Effects

In the first hour or so after a dose, most people feel some mix of dissociation (feeling detached from your body or surroundings, with time, space or sounds seeming distorted), dizziness or a spinning sensation, sleepiness, numbness, anxiety, nausea, a feeling of being drunk and headache. Blood pressure rises temporarily in many people. These effects are why the two-hour observation exists. They usually fade the same day, and nausea and vomiting tend to become less frequent as treatment continues. Spravato carries a boxed warning, the U.S. Food and Drug Administration's (FDA) most prominent kind, for sedation, dissociation, slowed breathing, abuse and misuse, and suicidal thoughts and behaviors. Deep sedation, rare loss of consciousness and rare cases of seriously slowed breathing have occurred, which is why breathing and oxygen are watched in the clinic. As with other antidepressants, suicidal thoughts and behaviors increased in people 24 and younger in short-term studies of antidepressants. Worsening depression or new or stronger thoughts of suicide should be reported to the prescriber right away. Some people notice more frequent, urgent or painful urination. Bladder inflammation has been reported with long-term ketamine misuse, though not in esketamine studies lasting up to a year, so urinary symptoms are worth mentioning to your care team.

Interactions & Warnings

Spravato is not used in people with an aneurysm (a weakened, bulging blood vessel, such as in the aorta or the brain), an arteriovenous malformation (an abnormal tangle of blood vessels), a history of bleeding in the brain, or an allergy to esketamine or ketamine. Because of the temporary rise in blood pressure, people with heart or blood vessel disease, past stroke or high blood pressure need a careful weighing of risk, and a high reading before a session may mean the dose is delayed. Other things that cause drowsiness, such as benzodiazepines (sedative and anti-anxiety medicines), opioid pain medicines and alcohol, can deepen sedation. Stimulants such as amphetamine or methylphenidate products and modafinil, and MAOIs (monoamine oxidase inhibitors, an older class of antidepressants), can push blood pressure higher. Your prescriber should know every medicine and supplement you take. Esketamine is a controlled substance that can be misused, so a history of drug or alcohol problems is weighed before starting and watched during treatment. It is not recommended during pregnancy because animal studies suggest possible harm to a developing baby; anyone who could become pregnant should discuss pregnancy planning and prevention, and treatment is stopped if pregnancy occurs. Esketamine passes into breast milk, and breastfeeding is not recommended during treatment.

What to Expect

A treatment day takes a good part of a morning or afternoon: preparation, a dose spread over about ten minutes, at least two hours of observation, and then no driving for the rest of the day. In studies, thinking and reaction time were measurably slower about 40 minutes after a dose and back to normal by around two hours. Some people notice their mood lift within the first days, sooner than with standard antidepressants, but on average the added benefit over an oral antidepressant alone is modest, and not everyone responds. For treatment-resistant depression, the prescriber reviews progress at the end of the first four weeks to decide whether to continue. Among people who did improve, continuing esketamine cut the risk of relapse roughly in half compared with stopping it. Over time, sessions are spaced to the least frequent schedule that keeps symptoms in check, and in studies lasting one and three years, thinking and memory stayed stable. The schedule is a real commitment, with travel, time away from work and a ride home after each session. If you miss sessions and your depression worsens, your prescriber may return you to a more frequent schedule.

Questions to Ask Your Doctor

  1. 1.Why is esketamine a better next step for me than another antidepressant, a medication combination or a different kind of treatment?
  2. 2.How will we judge after four weeks whether it is working, and what happens if it is not?
  3. 3.Do my blood pressure, heart health or any history of substance use change whether this is safe for me?
  4. 4.Which of my other medicines, such as sleep aids, pain medicines or stimulants, should we review before I start?
  5. 5.How long might I need sessions, and how would we decide to space them out or stop?

Last reviewed • Oct 2026

Educational content, not medical advice.